Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | Choosing the best treatment for your follicular lymphoma patient

Nathan Fowler • 1 Jun 2018
ASCO 2018
B-Cell Lymphoma Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma Bendamustine Lenalidomide Rituximab

Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, Nathan Fowler, MD, of the MD Anderson Cancer Center, Houston, TX, discusses the decision-making process when selecting the best frontline treatment for a follicular lymphoma patient. Prof. Fowler highlights the factors that should be taken into consideration, including specific comorbities, disease progression and side effects.

More from Nathan Fowler

1:36
ELARA: Tisa-cel in follicular lymphoma
Nathan Fowler • 12 Dec 2021
0:39
10 year follow up of rituximab and lenalidomide in low tumor burden FL
Nathan Fowler • 12 Dec 2021
1:03
RELEVANCE: Rituximab and lenalidomide in FL
Nathan Fowler • 12 Dec 2021
3:44
ELARA: tisa-cel in R/R follicular lymphoma
Nathan Fowler • 18 Jun 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals